This protocol covers venous thromboembolism — specifically lower limb deep vein thrombosis — arising in a patient with cancer that has gastrointestinal or genitourinary involvement. This combination creates a high risk for mucosal bleeding that must be central to any anticoagulation decision.
Patients with gastrointestinal and genitourinary malignancies represent a recognised exception within cancer-associated VTE management. Their elevated mucosal bleeding risk means that anticoagulant selection is not interchangeable with other cancer-DVT populations — certain agents carry a meaningfully higher bleeding risk in this setting compared with others.
Anticoagulation is recommended, but the agent is specifically chosen for its safety profile in this high mucosal bleeding risk population. Not all anticoagulants perform equivalently here — the selection between available options is guided by comparative bleeding data in this subgroup. The full protocol details which agents are preferred and how to proceed.
Patients with gastrointestinal and genitourinary malignancies may constitute an exception to the above recommendation, as there is an increased risk of bleeding in these patients with use of rivaroxaban and edoxaban when compared with LMWH, but apixaban seems to be noninferior to LMWH, with no increased risk of major bleeding.
Thus, apixaban or LMWH is recommended in patients with high risk for mucosal bleeding.
View source ↗